Cyrus Desouza, MD
Endocrinology, Diabetes & Metabolism · Omaha, NENPI 1346298148
Payments from drug & device makers
Across 4,220 payments — averaging $861.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$2.2M
- Novartis$539K
- Eli Lilly$336K
- Sanofi US Services Inc.$134K
- Kowa Research Institute, Inc.$97K
- Amgen$80K
- plus $217K from 18 others
Across 24 payments — averaging $462.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk$7K
- Eli Lilly$1K
- Gilead$1K
- Novo Nordisk AS$1K
- Sanofi-aventis U.S. LLC$509
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 4,033 | $2,233,436 |
| Novartis | 13 | $539,457 |
| Eli Lilly | 31 | $335,765 |
| Sanofi US Services Inc. | 17 | $134,184 |
| Kowa Research Institute, Inc. | 42 | $97,344 |
| Amgen | 3 | $80,303 |
| Lexicon Pharmaceuticals, Inc. | 1 | $64,562 |
| Novo Nordisk | 27 | $42,053 |
| Pfizer | 7 | $40,265 |
| Genentech, Inc. | 6 | $27,216 |
| Gilead | 7 | $25,495 |
| Bayer | 14 | $7,682 |
| Janssen Research & Development, LLC | 1 | $5,739 |
| Boehringer Ingelheim International GmbH | 5 | $1,222 |
| AstraZeneca | 2 | $1,109 |
| Abbott | 2 | $600 |
| Dexcom, Inc. | 2 | $365 |
| Ascendis Pharma Endocrinology Inc | 1 | $161 |
| Boehringer Ingelheim | 1 | $136 |
| BD | 1 | $108 |
| Corcept Therapeutics | 1 | $102 |
| Medtronic | 1 | $62 |
| Ascensia Diabetes Care US Inc. | 1 | $23 |
| Boston Scientific | 1 | $18 |
How this compares
$3,637,406 in reported general payments places this provider in the 95th percentile of 43 endocrinology, diabetes & metabolism providers in Nebraska.
See all endocrinology, diabetes & metabolism providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Omaha
- Vijay ShivaswamyOmaha$1.3M
- Robert AndersonOmaha$736K
- Claire BakerOmaha$538K
- Sarah KonigsbergOmaha$251K
- Andjela DrincicOmaha$192K
- Marium IlahiOmaha$170K
- Robert ReckerOmaha$115K
- Timothy WahlOmaha$41K
- Marc RendellOmaha$25K
- Anery PatelOmaha$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.